Efficacy and Safety of the Treatment of Pyruvate Dehydrogenase Deficiency Patients With Glycerol Phenylbutyrate (RAVICTI) (PDH-RAVICTI)
A Phase II, Multicentric, Prospective, Non-comparative Clinical Trial to Assess the Efficacy and Safety of the Treatment of Pyruvate Dehydrogenase Deficiency (PDH) Patients With Glycerol Phenybutyrate (RAVICTI®)
Sponsor: Assistance Publique - Hôpitaux de Paris
Listed as NCT06887777, this PHASE2 trial focuses on Pyruvate Dehydrogenase Complex Deficiency Disease and remains actively recruiting participants. Sponsored by Assistance Publique - Hôpitaux de Paris, it has been updated 4 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
4 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2025 — Feb 2026 [monthly]
Not Yet Recruiting PHASE2
-
May 2025 — Jun 2025 [monthly]
Not Yet Recruiting PHASE2
-
Apr 2025 — May 2025 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Assistance Publique - Hôpitaux de Paris
- URC-CIC Paris Descartes Necker Cochin
For direct contact, visit the study record on ClinicalTrials.gov .